Literature DB >> 3681190

Somatically mutated forms of a major anti-p-azophenylarsonate antibody variable region with drastically reduced affinity for p-azophenylarsonate. By-products of an antigen-driven immune response?

T Manser1, B Parhami-Seren, M N Margolies, M L Gefter.   

Abstract

The pivotal role played by antigen in the clonal selection of B cells for initial participation in an immune response is well established. Antigen selective mechanisms ensure that antigen-binding antibodies are produced during all stages of the immune response. However, antibodies that lack specificity for the immunogen might also be produced during the course of an antigen-driven immune response . It has been suggested that, through idiotype-antiidiotype network interactions within the immune system, production of antibodies that lack specificity for the immunogen but that share idiotopes with antigen-binding antibodies could result (1). In addition, data obtained by a number of investigators suggest that somatic mutation of antibody V region genes occurs at a rate of 10(-3)/basepair/cell division in B cells participating in an immune response (2, 3). One outcome of such V region structural alteration could be antibodies that lack, or have drastically reduced affinity for the immunogen . We sought to identify and characterize some of the antibody by-products of the antigen-driven immune response that are expected to be created by the mechanisms described above.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3681190      PMCID: PMC2189635          DOI: 10.1084/jem.166.5.1456

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  20 in total

1.  Complete heavy and light chain variable region sequence of anti-arsonate monoclonal antibodies from BALB/c and A/J mice sharing the 36-60 idiotype are highly homologous.

Authors:  E Juszczak; R I Near; M L Gefter; M N Margolies
Journal:  J Immunol       Date:  1984-11       Impact factor: 5.422

2.  Junctional diversity is essential to antibody activity.

Authors:  D J Jeske; J Jarvis; C Milstein; J D Capra
Journal:  J Immunol       Date:  1984-09       Impact factor: 5.422

3.  Structural diversity among anti-p-azophenylarsonate monoclonal antibodies from A/J mice; comparison of Id- and Id+ sequences.

Authors:  M N Margolies; A Marshak-Rothstein; M L Gefter
Journal:  Mol Immunol       Date:  1981-12       Impact factor: 4.407

4.  Isolation of hybridomas expressing a specific heavy chain variable region gene segment by using a screening technique that detects mRNA sequences in whole cell lysates.

Authors:  T Manser; M L Gefter
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

5.  Towards a network theory of the immune system.

Authors:  N K Jerne
Journal:  Ann Immunol (Paris)       Date:  1974-01

6.  Complete amino acid sequence of the heavy-chain variable region from an A/J mouse antigen-nonbinding monoclonal antibody bearing the predominant arsonate idiotype.

Authors:  J A Smith; M N Margolies
Journal:  Biochemistry       Date:  1984-09-25       Impact factor: 3.162

7.  The strain A anti-p-azophenylarsonate major cross-reactive idiotypic family includes members with no reactivity toward p-azophenylarsonate.

Authors:  L J Wysocki; V L Sato
Journal:  Eur J Immunol       Date:  1981-10       Impact factor: 5.532

8.  Anti-oxazolone hybridomas and the structure of the oxazolone idiotype.

Authors:  M Kaartinen; G M Griffiths; P H Hamlyn; A F Markham; K Karjalainen; J L Pelkonen; O Mäkelä; C Milstein
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

9.  Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin.

Authors:  D McKean; K Huppi; M Bell; L Staudt; W Gerhard; M Weigert
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

10.  Regulation of azophenylarsonate-specific repertoire expression. 1. Frequency of cross-reactive idiotype-positive B cells in A/J and BALB/c mice.

Authors:  N H Sigal
Journal:  J Exp Med       Date:  1982-11-01       Impact factor: 14.307

View more
  8 in total

1.  A human anti-insulin IgG autoantibody apparently arises through clonal selection from an insulin-specific "germ-line" natural antibody template. Analysis by V gene segment reassortment and site-directed mutagenesis.

Authors:  Y Ichiyoshi; M Zhou; P Casali
Journal:  J Immunol       Date:  1995-01-01       Impact factor: 5.422

2.  Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations.

Authors:  C Chen; V A Roberts; S Stevens; M Brown; M P Stenzel-Poore; M B Rittenberg
Journal:  EMBO J       Date:  1995-06-15       Impact factor: 11.598

3.  Characterization of somatically mutated S107 VH11-encoded anti-DNA autoantibodies derived from autoimmune (NZB x NZW)F1 mice.

Authors:  S M Behar; D L Lustgarten; S Corbet; M D Scharff
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

4.  Evolution of antibody structure during the immune response. The differentiative potential of a single B lymphocyte.

Authors:  T Manser
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307

5.  Different epitope structures select distinct mutant forms of an antibody variable region for expression during the immune response.

Authors:  S Fish; M Fleming; J Sharon; T Manser
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

6.  Mouse Vk gene classification by nucleic acid sequence similarity.

Authors:  R Strohal; A Helmberg; G Kroemer; R Kofler
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

7.  Generation and analysis of random point mutations in an antibody CDR2 sequence: many mutated antibodies lose their ability to bind antigen.

Authors:  C Chen; V A Roberts; M B Rittenberg
Journal:  J Exp Med       Date:  1992-09-01       Impact factor: 14.307

8.  Tracing the development of single memory-lineage B cells in a highly defined immune response.

Authors:  A H Liu; P K Jena; L J Wysocki
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.